Lactulose
When ATH:
A06AD11
Characteristic.
White powder, soluble in water. As impurities may contain galactose (no more 16%), laktozu (12%), epilaktozu (8%), fructose (1%).
Pharmacological action.
Stimulating peristalsis, laxative, hypoazotemic.
Application.
Constipation (incl. chronic); the need to soften the stool for medical purposes (hemorrhoids, need surgery on the colon and / or anal, pain after the removal of hemorrhoids, postoperatively); hepatic encephalopathy, including to whom and Preko (Treatment and Prevention); ammoniemia; intestinal dysbiosis; enteritis, by salmonella, şigellami, salmonellonositelstvo; putrid dyspepsia syndrome (in infants as a result of acute food poisoning).
Contraindications.
Hypersensitivity, galactosemia, bowel obstruction, rectal bleeding (the cause of which is not hemorrhoids), round- or ileostomy, suspected appendicitis.
Pregnancy and breast-feeding.
Category actions result in FDA - B. (The study of reproduction in animals revealed no risk of adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not done.)
Side effects.
Flatulence, diarrhea, abdominal pain, loss of electrolytes.
Cooperation.
Antibiotics (neomycin) and non-absorbable antacids reduce the effect of.
Overdose.
Symptoms: diarrhea, abdominal pain.
Treatment: the drug should be discontinued.
Dosing and Administration.
Inside. Dose set individually. When liver encephalopathy adults appoint up to 45-90 ml of syrup in 2-3 reception (up to 90-190 ml/day), for other indications — 15-45 mL/day. Children over 1 year 5-15 ml/day, younger 1 year - 5 ml / day.
Precautions.
To use caution in patients with diabetes (especially in the treatment of hepatic encephalopathy). When gastrocardiac syndrome should gradually increase the dose, to avoid flatulence; flatulence usually disappear on their own after 2-3 days of treatment. You can not assign to the background of abdominal pain, nausea and vomiting. When the diarrhea treatment cancel. Long-term treatment (more 6 Months) higher doses should regularly monitor the level of serum electrolytes.
Cooperation
Active substance | Description of interaction |
Calcium carbonate | FKV. Reduces the drop in colonic pH, called lactulose, and prevents the development effect. |
Magnesium carbonate | FKV. Reduces the drop in colonic pH, called lactulose, and prevents the development effect. |
Neomycin | FMR: antagonizm. Reduces effect. |